Keywords: Johnson & Johnson, Zytiga, Janssen R&D, Prostate cancer, Ph III

Unblinded Zytiga study meets endpoints in prostate cancer

Article | 09 March 2012

Print This

Janssen Research & Development, a subsidiary of US health care giant Johnson & Johnson (NYSE: JNJ), has unblinded the Phase ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in